{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:01:32Z","timestamp":1789455692903,"version":"build-2803163510"},"reference-count":45,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,7,31]],"date-time":"2008-07-31T00:00:00Z","timestamp":1217462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Arsenic trioxide (As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub>) has established clinical activity in acute promyelocytic leukaemia and has pre\u2010clinical data suggesting activity in lymphoid malignancies. Cell death from As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub> may be the result of oxidative stress. Agents which deplete intracellular glutathione, such as ascorbic acid (AA), may potentiate arsenic\u2010mediated apoptosis. This multi\u2010institution phase II study investigated a novel dosing schedule of As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub> and AA in patients with relapsed or refractory lymphoid malignancies. Patients received As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub> 0.25\u2009mg\/kg IV and AA 1000\u2009mg IV for five consecutive days during the first week of each cycle followed by twice weekly infusions during weeks 2\u20136. Cycles were repeated every 8 weeks. The primary end point was objective response. In a subset of patients, sequential levels of intracellular glutathione and measures of Bcl\u20102 and Bax gene expression were evaluated in peripheral blood mononuclear cells during treatment. Seventeen patients were enrolled between March 2002 and February 2004. The median age was 71, and the majority of enrolled patients had non\u2010Hodgkin's lymphoma (12\/17). Sixteen patients were evaluable, and one patient with mantle cell lymphoma achieved an unconfirmed complete response after five cycles of therapy for an overall response rate of 6%. The trial, which had been designed as a two\u2010stage study, was closed after the first stage analysis due to lack of activity. Haematologic toxicities were the most commonly reported events in this heavily pre\u2010treated population, and comprised the majority of grade 3 and 4 toxicities. Intracellular depletion of glutathione was not consistently observed during treatment. As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub> and AA in this novel dosing strategy was generally well tolerated but had limited activity in patients with relapsed and refractory lymphoid malignancies. Copyright \u00a9 2008 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.870","type":"journal-article","created":{"date-parts":[[2008,7,31]],"date-time":"2008-07-31T08:07:13Z","timestamp":1217491633000},"page":"11-16","source":"Crossref","is-referenced-by-count":31,"title":["Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study"],"prefix":"10.1002","volume":"27","author":[{"given":"JE","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PM","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JM","family":"Kolesar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HG","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FA","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GA","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Werndli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HH","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BS","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,31]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"58","article-title":"Arsenic trioxide treated 72 cases of acute promyelocytic leukemia","volume":"17","author":"Zhang P","year":"1996","journal-title":"Chin J Hematol"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","article-title":"Use of arsenic trioxide in the treatment of acute promyelocytic leukemia (APL): clinical efficacy and pharmacokinetics in relapsed patients","volume":"89","author":"Shen ZX","year":"1997","journal-title":"Blood"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.10.3315.422k16_3315_3324"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811053391901"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.7903"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.9503"},{"key":"e_1_2_1_8_2","first-page":"260b","article-title":"Major hematologic response in a patient with myelodysplasia to arsenic trioxide","volume":"96","author":"Dutcher JP","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402599"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.6-suppl_2-17"},{"issue":"1","key":"e_1_2_1_11_2","first-page":"123a","article-title":"Marked antitumor effect of arsenic trioxide (As2O3) in high risk refractory multiple myeloma","volume":"94","author":"Munshi NC","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04941.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401112"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.9.772"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.2.562.562_562_570"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00869.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402735"},{"key":"e_1_2_1_18_2","first-page":"3345","article-title":"Use of arsenic trioxide (As2O3) in the treatment of acute promylecytic leukemia (APL): As2O3 exerts dose\u2010dependent dual effects on APL cells","volume":"89","author":"Chen GQ","year":"1997","journal-title":"Blood"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.6-suppl_2-22"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.2102"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood.V93.1.268","article-title":"Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox systems","volume":"93","author":"Dai J","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690766"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.3.805"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1191\/0960327102ht307oa"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-2863(03)00076-7"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02608.x"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute\u2010sponsored Working Groups guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson BD","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(69)90064-5"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11314"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3532"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06280.x"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1385\/MO:23:2:263"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.3.1014.003k04_1014_1022"},{"key":"e_1_2_1_36_2","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood.V88.3.1052.1052","article-title":"In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB\u20104 cell apoptosis with downregulation of Bcl\u20102 expression and modulation of PML\u2010RAR\u03b1\/PML proteins","volume":"88","author":"Chen GQ","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500305851"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.1.194"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.23.1789"},{"issue":"7","key":"e_1_2_1_40_2","first-page":"1969","article-title":"Glutathione, ascorbate, and cellular protection","volume":"54","author":"Meister A","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190412331272686"},{"key":"e_1_2_1_42_2","first-page":"3658","article-title":"Feasibility and correlates of arsenic trioxide combined with ascorbic acid\u2010mediated depletion of intracellular glutathione for the treatment of relapsed\/refractory multiple myeloma","volume":"8","author":"Bahlis NJ","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1154"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21386"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21925"},{"key":"e_1_2_1_46_2","first-page":"1105","article-title":"A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia","volume":"91","author":"Litzow MR","year":"2006","journal-title":"Haematologica"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.870","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T01:48:53Z","timestamp":1699926533000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,31]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1002\/hon.870"],"URL":"https:\/\/doi.org\/10.1002\/hon.870","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,31]]}}}